Alimera Sciences Inc (ALIM) 1.49 $ALIM Alimera Sciences

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 5:20 PM

Alimera Sciences Inc (ALIM) 1.49 $ALIM

Alimera Sciences to Present at the LD Micro Invitational Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the LD Micro Invitational Conference, to be held June 7 - 9, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The Company's presentation will take place Wednesday, June 8, 2016 at 8:30 AM Pacific Time.
ALIM: 1.49 (-0.02)

Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien(R) At 12 Months
GlobeNewswire - Mon May 23, 3:00PM CDT
Despite other prior treatments, improvements in visual acuity and retinal thickness were seen in the majority of patients
ALIM: 1.49 (-0.02)

Alimera Sciences to Present at the UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 6:30AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the UBS Global Healthcare Conference, to be held May 23 - 25, 2016 at the The Grand Hyatt in New York City, New York. The Company's presentation will take place Monday, May 23, 2016 at 11:30 AM Eastern Time.
ALIM: 1.49 (-0.02)

Alimera Sciences' ILUVIEN(R) Data Presented at SFO 2016
GlobeNewswire - Wed May 11, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from six ILUVIEN post marketing studies were presented during the French Society of Ophthalmology 122nd Congress (SFO 2016) in Paris May 7-10.
ALIM: 1.49 (-0.02)

Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO
PR Newswire - Fri May 06, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from seven ILUVIEN® post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, May 1-5.
ALIM: 1.49 (-0.02)

Alimera Sciences reports 1Q loss
Automated Insights - Wed May 04, 6:48PM CDT
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Wednesday reported a loss of $11.1 million in its first quarter.
ALIM: 1.49 (-0.02)

Alimera Sciences Announces First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:23PM CDT
-- First quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN(R) sales in the U.S.
ALIM: 1.49 (-0.02)

Stonegate Capital Partners Initiates Coverage on Alimera Sciences
ACCESSWIRE - Wed Apr 27, 8:02AM CDT
DALLAS, TX / ACCESSWIRE / April 27, 2016 / Stonegate Capital Partners initiates research coverage on Alimera Sciences, Inc. (NASDAQ: ALIM).
ALIM: 1.49 (-0.02), REGN: 357.14 (+5.22)

Alimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016
GlobeNewswire - Tue Apr 26, 8:58AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the period ended March 31st, 2016, at the close of the financial markets on May 4, 2016.
ALIM: 1.49 (-0.02)

New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 10.51 (+0.21), ALIM: 1.49 (-0.02), ARES: 14.02 (+0.32), AXTA: 28.02 (+0.06), ARNA: 1.91 (+0.06)

New Strong Sell Stocks for April 18th
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 6:42AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
CRME: 5.00 (+0.05), ALIM: 1.49 (-0.02), CAR: 34.81 (+1.34), BAC: 14.04 (+0.43), CWT: 32.72 (+0.60)

New Strong Sell Stocks for March 31st
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 7:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXE: 60.65 (+1.15), ALIM: 1.49 (-0.02), AMD: 5.21 (+0.19), CWT: 32.72 (+0.60), ATRS: 1.01 (unch)

New Strong Sell Stocks for March 16th
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 7:29AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
FITB: 19.11 (+0.67), CECE: 8.85 (+0.25), ALIM: 1.49 (-0.02), FBC: 23.69 (+0.45), FCFS: 50.41 (+1.76)

Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Wed Mar 02, 6:48PM CST
-- Annual revenue increased 167% for 2015 compared to 2014
ALIM: 1.49 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Weifang's Cultural Resurgence: A Global Epigraphy Fest

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Masimo's smartSET™ Revolutionizes Patient Monitoring

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Innventure Faces Major Lawsuit Over Misleading Investors

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Voter Events by Valley Community Healthcare Aim to Empower

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Hyliion Class Action Deadline Nears for Investors

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

AEVEX Facing Class Action Deadline Amid Stock Turmoil

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

LG OLED evo W6: UAE Roadshow Starts with a Bang

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...